MRS2 and mitochondrial gene networks in endometrial cancer: mechanisms, biomarkers, and therapeutic implications
PeerJ · 2026
DOI: 10.7717/peerj.20409 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2026. Verfasst von Leyi Huang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Gynecologic Oncology, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatri…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Mitochondria, Gene Regulatory Networks, Mitochondrial Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujian Provincial Natural Science Foundation of China, Startup Fund for scientific research, Fujian Medical University.
Abstract (Originalsprache)
Magnesium ions and their transport proteins are increasingly recognized for their critical roles in tumor progression. However, their specific mechanisms in endometrial cancer (EC) remain poorly understood. This study investigated the role of Mitochondrial RNA Splicing 2 protein (MRS2), a key mitochondrial magnesium transporter, and its associated genes, in regulating mitochondrial function and the invasive and metastatic capabilities of EC cells. Using a combination of experimental approaches including lactate detection, flow cytometry, immunofluorescence, CCK8 assays, and Transwell migration assays, along with bioinformatics analysis, we investigated the relationship between lactate levels and MRS2 expression in endometrial cancer cells (KLE). Our findings suggest that elevated lactate levels are associated with increased MRS2 expression in mitochondria. This correlation was further linked to enhanced reactive oxygen species (ROS) production and altered expression of mitochondrial-related genes. Notably, MRS2 knockdown resulted in reduced proliferation of KLE cells, supporting a potential functional role of MRS2 in endometrial cancer progression. These findings provide new insights into the molecular mechanisms underlying EC progression and highlight MRS2 as a potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Gynecologic Oncology, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China.
- Department of Biochemistry and Molecular Biology, Fujian Medical University, Fuzhou, Fujian, China.
- Medical Genetic Diagnosis and Therapy Center, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fujian Key Laboratory for Pre…
- The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian,…
- Experimental Teaching Center of Basic Medicine, Fujian Medical University, Fuzhou, China.
Förderung
- Fujian Provincial Natural Science Foundation of China
- Startup Fund for scientific research, Fujian Medical University
Zitieren
APA
Huang, L., Kang, Y., Lin, W., Chen, J., Huang, Y., Zhang, Y., Shen, Y., Wu, Z., Chen, S., Zheng, S., Wang, Y., Lin, R., & Qi, Y. (2026). MRS2 and mitochondrial gene networks in endometrial cancer: mechanisms, biomarkers, and therapeutic implications. PeerJ. https://doi.org/10.7717/peerj.20409
Vancouver
Huang L, Kang Y, Lin W, Chen J, Huang Y, Zhang Y, et al. MRS2 and mitochondrial gene networks in endometrial cancer: mechanisms, biomarkers, and therapeutic implications. PeerJ. 2026. doi:10.7717/peerj.20409
BibTeX
@article{Huang2026,
author = {Huang, Leyi and Kang, Yafang and Lin, Wenyu and Chen, Jiaxi and Huang, Yuxuan and Zhang, Yan and Shen, Yihan and Wu, Zeyu and Chen, Sihao and Zheng, Shaoqing and Wang, Yiyang and Lin, Renxi and Qi, Yuanlin},
title = {MRS2 and mitochondrial gene networks in endometrial cancer: mechanisms, biomarkers, and therapeutic implications},
journal = {PeerJ},
year = {2026},
doi = {10.7717/peerj.20409}
}
EUVIMED